Nasonex (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors in the nasal mucosa, modulating gene transcription to suppress pro‑inflammatory cytokines, reduce vascular permeability, and inhibit immune‑cell activation, thereby decreasing nasal inflammation.

The dosing regimen for Nasonex is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. The prescriber will specify the number of sprays per nostril and the frequency of administration.

The safety of mometasone furoate nasal spray during pregnancy has not been definitively established; it is classified as a pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) offers a high‑potency anti‑inflammatory effect with once‑daily dosing for many patients, similar to other intranasal corticosteroids such as fluticasone propionate or budesonide. Choice among agents often depends on individual response, dosing convenience, and formulary considerations rather than marked efficacy differences.

Store Nasonex at room temperature, below 25 °C, in its original packaging to protect from moisture and direct sunlight. Keep the spray bottle tightly closed when not in use and avoid freezing. Do not share the device with others.

Nasonex is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The prescribed number of sprays per nostril is set by the clinician.

Although rare, serious adverse events can include adrenal suppression, severe allergic reactions such as anaphylaxis, nasal septum perforation, and opportunistic infections like fungal sinusitis. Patients should seek immediate medical attention if they experience unusual bleeding, severe headache, visual changes, or signs of systemic corticosteroid effects.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those for whom systemic corticosteroid exposure is contraindicated, unless directed by a physician.